What it sells
Develops oligonucleotide (siRNA) therapies designed to reach and enter the specific cells that drive disease, starting with programs in FSHD muscular dystrophy and heart failure.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-15 | Series B | $135M | Juvia Group (lead) | news.google.com |
| 2026-10-15 | — | $135M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.